- Home
- RLYB vs BNGO Comparison
RLYB vs BNGO Comparison
Compare RLYB & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLYB | BNGO |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 24.3M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RLYB | BNGO |
|---|---|---|
| Price | $0.69 | $1.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | ★ 185.6K | 183.8K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $674,000.00 | ★ $28,720,000.00 |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | $24.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.71 | N/A |
| 52 Week Low | $0.22 | $1.45 |
| 52 Week High | $1.08 | $22.80 |
Technical Indicators
Market Signals| Indicator | RLYB | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 49.41 | 40.14 |
| Support Level | $0.71 | $1.61 |
| Resistance Level | $0.80 | $1.63 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 44.06 | 9.52 |
Price Performance
Historical ComparisonAbout RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.